Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
Clinical trial NCT02006043 · UNKNOWN
Trial details
- NCT number
- NCT02006043
- Sponsor
- Li Zhang
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2016-12-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.